Luca Santarelli’s PhIII is good to go, he has a new app to stop Covid-19 from infecting the data and $110M to pave the way
Luca Santarelli barely skipped a beat when he sold Therachon to Pfizer last year in an $810 million deal. The pharma giant wanted the biotech’s drug for dwarfism, and got it.
Santarelli, meanwhile, immediately spun out with a new company called VectivBio, taking their Phase II drug apraglutide for short bowel syndrome.
The Roche vet focused on executing on the Phase II with a $35 million changeup round, and is now pivoting to Phase III with a mega-raise of $110 million. Still on the to-do list are new deals to beef up the very thin 1-drug pipeline with more rare disease drugs. And he’s already starting to lay the foundation for commercialization work, anticipating that he can have registration data in hand in early 2023.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.